Myasthenia gravis ranks as the most common neuromuscular junction (NMJ) disorder, characterized primarily by a highly diverse presentation. Distinguished as a frontrunner in rare disease diagnostics, including intricate conditions such as myasthenia gravis, our company excels through our expertise and inventive strategies. We offer a range of IVD test kits, reagents, and diagnostic equipment development services to enhance precision and rapid diagnosis of myasthenia gravis.
Overview of Myasthenia Gravis
Myasthenia gravis, an autoimmune condition, arises from specific antibodies targeting various postsynaptic components of the neuromuscular junction, leading to fatigue-inducing muscle weakness. The prevalence of myasthenia gravis stands at around 125 cases per million individuals. In younger age groups, a slight female predominance is observed, while in older age brackets, males have a higher proportion.
Myasthenia gravis being autoimmune, is associated with detectable antibodies against acetylcholine receptor (AChR), muscle-specific tyrosine kinase (MuSK), lipoprotein-related peptide 4 (LRP4), agrin, titin, and ryanodine located on the postsynaptic membrane at the NMJ.
Fig.1 Pathogenesis of myasthenia gravis. (Dresser, L., et al., 2021)
Biomarkers Development for Myasthenia Gravis
The development of biomarkers for myasthenia gravis has seen significant progress in recent years, to enhance diagnosis, track disease progression, and gauge therapy effectiveness. These biomarkers are key in improving diagnostic precision, categorizing individuals based on their condition, and tailoring personalized therapy strategies for those with myasthenia gravis.
Anti-Acetylcholine Receptor Antibodies
AChR antibodies are present in about 85% of myasthenia gravis individuals with generalized symptoms. These antibodies play a crucial role in the pathogenesis of myasthenia gravis and are a key diagnostic biomarker.
Antibodies to MuSK
MuSK antibodies are found in a subset of myasthenia gravis individuals, particularly those with MuSK-positive myasthenia gravis. Detection of MuSK antibodies aids in the diagnosis of this specific subtype.
Antibodies to Anti-LRP4
LRP4 antibodies have been identified in a proportion of myasthenia gravis individuals who are negative for AChR and MuSK antibodies, expanding the spectrum of diagnostic biomarkers for myasthenia gravis.
Titin Antibodies
Titin antibodies have been associated with a subtype of myasthenia gravis characterized by thymoma and late-onset muscle weakness. Their presence can help in diagnosing this specific form of myasthenia gravis.
IVD Kits for Myasthenia Gravis
| Kits |
Applications |
Method of detection |
| AChR-Ab ELISA Kit |
Recognizes human AChR-Ab in samples |
ELISA |
| AChR-Ab Detection Kit |
Quantitative determination of AChR autoantibodies in human serum |
Radioimmunoprecipitation Assay (RIPA) |
| AChR-Ab CBA Kit |
Uses immunofluorescence for AChR autoantibody detection |
Cell-based Assay (CBA) |
| MuSK-Ab ELISA Kit |
Qualitative and quantitative determination of autoantibodies against MuSK in human serum |
ELISA |
| LRP4 Autoantibody Detection Kit |
Detects anti-LRP4 in the sera of individuals |
ELISA |
Our Services
With deep expertise in rare diseases, we harness state-of-the-art technologies and a diverse team of experts to deliver a wide array of IVD product development services. Our advanced point-of-care testing development services yield accurate and swift diagnostic solutions, enabling prompt decision-making and therapy strategies. Additionally, our companion diagnostic development service aims to customize therapeutic decisions based on individual traits and needs.
Our commitment to precision diagnosis keeps us leading the way in diagnostic progress, constantly refining our approaches to integrate the most recent breakthroughs in the field. Offering a full spectrum of diagnostic development services, we cater to your varied scientific research requirements, aiming to swiftly and precisely diagnose diseases and expedite the implementation of individualized therapeutics.
If you are interested in our services, don't hesitate to contact us for further details.
References
- Rousseff, Rossen T. "Diagnosis of Myasthenia Gravis." Journal of clinical medicine 10.8 (2021): 1736.
- Dresser, Laura et al. "Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations." Journal of clinical medicine 10.11 (2021): 2235.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
